Haematologica Reports 2005; 1(issue 8):
37-40[prev][index][next]
CD30: a suitable target for
immunotherapy?
Borchmann P
University of Cologne, 1st Department of Internal Medicine,
Cologne, Germany
The CD30 antigen and its physiological
function
CD30 is a 120 kDa transmembrane glycoprotein belonging to the
TNF-receptor superfamily and lacking an intracellular death domain.
Physiologically, expression of CD30 is found on virus-infected
lymphocytes and on a small subset of activated T cells. Furthermore
this receptor is involved in the negative selection process of
auto-reactive lymphocytes.1 The CD30 ligand (CD30L) is
present on activated T cells, resting B cells, and granulocytes. As
shown for most other members of the TNF-receptor family signaling
via CD30 is pleiotropic and may result in different responses
including apoptosis, differentiation and growth stimulation even in
monoclonal cells. This response may depend on the developmental
status and environment of the cell.2 [>Read full article in PDF]
